Login to Your Account



Genentech Hardly 'Resistant': Up to $111M in Deal with RQx

By Randy Osborne
Staff Writer

Monday, February 11, 2013

Avalon Ventures scored again for the third time in recent weeks, as antibiotics-focused RQx Pharmaceuticals Inc. is expected to make public today a deal worth as much as $111 million with Genentech.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription